Relmada Therapeutics, Inc.
DE ˙ DB ˙ US75955J4022
5,30 € ↓ -0,05 (-0,93%)
2026-06-04
AKTIENPREIS
SecurityDE:4E2 / Relmada Therapeutics, Inc.
InstitutionPensionmark Financial Group, Llc
Latest Disclosed Ownership10,444 shares
Latest Disclosed Value $ 72,691
Pensionmark Financial Group, Llc ownership in 4E2 / Relmada Therapeutics, Inc.

On April 27, 2026 - Pensionmark Financial Group, Llc filed a 13F-HR form disclosing ownership of 10,444 shares of Relmada Therapeutics, Inc. (DE:4E2) valued at $57,442 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on March 13, 2026 disclosing 10,444 shares of Relmada Therapeutics, Inc.. This represents a change in shares of 0.00% during the quarter. The current value of the position is $55,353 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-27 2026-03-31 13F RELMADA THERAPEUTICS COM 75955J402 10,444 0 0.00 73 44.00 0.0012
2026-03-13 2025-12-31 13F/A-1 RELMADA THERAPEUTICS COM 75955J402 10,444 -200 -1.88 50 138.10 0.0008
2026-02-04 2025-12-31 13F RELMADA THERAPEUTICS COM 75955J402 10,444 -200 50 0.0010
2025-10-15 2025-09-30 13F RELMADA THERAPEUTICS COM 75955J402 10,644 -11,000 -50.82 21 75.00 0.0004
2025-08-04 2025-06-30 13F RELMADA THERAPEUTICS COM 75955J402 21,644 0 0.00 13 140.00 0.0003
2025-04-29 2025-03-31 13F RELMADA THERAPEUTICS COM 75955J402 21,644 -8,040 -27.09 6 -66.67 0.0002
2025-02-12 2024-12-31 13F RELMADA THERAPEUTICS COM 75955J402 29,684 -3,000 -9.18 15 -85.71 0.0004
2024-11-25 2024-09-30 13F/A-1 RELMADA THERAPEUTICS COM 75955J402 32,684 2,000 6.52 106 14.13 0.0033
2024-11-14 2024-09-30 13F RELMADA THERAPEUTICS COM 75955J402 32,684 2,000 106 0.0033
2024-08-15 2024-06-30 13F RELMADA THERAPEUTICS COM 75955J402 30,684 0 0.00 92 -35.21 0.0057
2024-05-15 2024-03-31 13F RELMADA THERAPEUTICS COM 75955J402 30,684 30,684 143 0.0204
2023-02-14 2022-12-31 13F RELMADA THERAPEUTICS COM 75955J402 0 -12,700 -100.00 0 -100.00
2022-11-14 2022-09-30 13F RELMADA THERAPEUTICS COM 75955J402 12,700 0 0.00 470 50.64 0.1116
2022-08-09 2022-06-30 13F RELMADA THERAPEUTICS COM 75955J402 12,700 -1,500 -10.56 312 -18.54 0.0655
2022-05-12 2022-03-31 13F RELMADA THERAPEUTICS COM 75955J402 14,200 0 0.00 383 45.63 0.0795
2022-02-11 2021-12-31 13F RELMADA THERAPEUTICS COM 75955J402 14,200 0 0.00 263 -29.30 0.0550
2021-11-12 2021-09-30 13F RELMADA THERAPEUTICS COM 75955J402 14,200 200 1.43 372 -16.96 0.0842
2021-08-12 2021-06-30 13F RELMADA THERAPEUTICS COM 75955J402 14,000 -500 -3.45 448 -7.82 0.1025
2021-05-17 2021-03-31 13F RELMADA THERAPEUTICS COM 75955J402 14,500 -1,650 -10.22 486 -17.49 0.1171
2021-02-16 2020-12-31 13F RELMADA THERAPEUTICS COM 75955J402 16,150 -350 -2.12 589 -5.15 0.1492
2020-11-13 2020-09-30 13F RELMADA THERAPEUTICS COM 75955J402 16,500 -400 -2.37 621 -1.43 0.2126
2020-08-14 2020-06-30 13F RELMADA THERAPEUTICS COM 75955J402 16,900 2,900 20.71 630 31.80 0.2203
2020-04-23 2020-03-31 13F RELMADA THERAPEUTICS COM 75955J402 14,000 1,000 7.69 478 -5.72 0.2219
2020-02-13 2019-12-31 13F RELMADA THERAPEUTICS COM 75955J402 13,000 13,000 507 0.1978
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.